EPAD - European Prevention of Alzheimer's Dementia

European Prevention of Alzheimer's Dementia

- Newsletter February 2020 -

---

Welcome

Dear Friends and Colleagues,

It’s February 2020 and we are just weeks away from the (delayed) end to the IMI period of EPAD. This will not be though the end of EPAD. There is still a massive amount of room to grow all our ideas and hopes within. The Change Management Team has been meeting on a weekly basis, working together (and with you) day by day over the last several months to fine tune the 5-component model and find funds to sustain each part of it from July 1st 2020. Just last week we met in Barcelona and spent most of that meeting discussing how we grow the trial centre network across Europe through collaboration with colleagues in North America who lead the GAP (Global Alzheimer’s Platform) Network. Next week in Amsterdam the Change Management Team is meeting will all the Trial Delivery Centers to discuss this collaboration further so that whatever the EPAD Trial Site Network looks like, it will be developed as a family of existing sites currently working on the cohort study or ready for undertaking EPAD trials.

For me – my personal priority - has been to secure funding for the Longitudinal Cohort Study (LCS). We did not want to compromise on quality and we did not want to make radical changes to the protocol post-IMI. We have developed a world-leading protocol through much discussion between all our partners – so much so that potential funders have been impressed massively by the depth of phenotyping, the quality and promises within our data and the ease with which it can be accessed. I am very confident we will have secured two years of funding over the next few weeks to maintain the LCS as it stands. The moment that confidence delivers a cast iron guarantee you will know.

We also have ongoing interest from companies wishing to use our trial platform but these discussions are fraught with challenges as so many factors have to align for the trials to go ahead. To this end we decided that from July we would be able to offer other roads to choose into the programme for the running of other trials e.g. smaller experimental medicine studies to compliment the ground-breaking EPAD Proof of Concept (PoC) we have all worked so hard to develop and which remains our priority.

The one thing perhaps that is going to be the easiest to maintain is The Academy. With the release of V1500.0 – we are witnessing a logarithmic increase in research activity on this database as well as the, now open-access, V500.0. In May V1500.0 will go open access and we can expect a substantial and ever-increasing number of abstracts at major international conferences from AAIC in Amsterdam forward.

This is a very challenging time in many ways – but the value we have created in the EPAD programme is staggering: The TDC Network, the Register and PrePAD system, the Data Access System and Analytical Environments, the largest cohort of its kind ever assembled, the ambitious but now fully formed trial platform with innovative master protocol, almost 100 EPAD Fellows sharing new horizons, scores of ongoing research projects, dozens of access requests for samples from the world’s largest ever biocollection purposed for neurodegenerative research and the indomitable spirit of the EPADistas –researchers and participants together - means that we will continue to succeed and bring knowledge and (one day) new treatments to prevent Alzheimer’s dementia.

In the words of the great Karen Carpenter – ‘We’ve only just begun’…….

This electronic newsletter will be published quarterly and be accessible via the EPAD website (http://ep-ad.org/) and inform the Alzheimer’s community on EPAD’s main achievements, upcoming events as well as allow you to meet the scientists who make it all happen.

We hope you enjoy this issue of the EPAD newsletter! Happy Reading!

Craig Ritchie

EPAD Co-Coordinator

---
---
EPAD passes the mark of 2,000 research participants for its Longitudinal Cohort Study

The Story behind the Picture

EPAD passes the mark of 2,000 research participants for its Longitudinal Cohort Study

The members of the EPAD initiative are glad to announce that its Longitudinal Cohort Study has recruited its 2,000th research participant in Sheffield (UK) this 15th January. Congratulations to the EPAD team in Sheffield (pictured). “Since we joined the project last year, patients in our area have been enthusiastic about the opportunities offered to them by participating in the EPAD …

Read more.

---

Meet the EPAD team

Interview with Graciela Muniz Terrera

Interview with Graciela Muniz Terrera

What is your current role in EPAD? I co-lead WP2 (Statistical/Methodology Engine Room) and I am also a member of the Balancing Committee that has important input in the selection of individuals into the EPAD Longitudinal Cohort Study. I have been involved in different roles in various publications using the EPAD data. Tell us a bit about the institution/company/organisation you …

Read more.

Interview with Martin Dvorak

What is your current role in EPAD? I work as a clinical lead at IQVIA where I manage the clinical research associates (CRAs) across all the countries that contribute to EPAD. I provide clinical trial expertise in accordance with protocols and with ICH GCP (International Conference on Harmonisation Good Clinical Practice). As clinical lead, I provide leadership to the clinical …

Read more.

---
EPAD design

EPAD presents @

• EPAD Investigator meeting, 20 February, Amsterdam (Netherlands)

---

Quarterly Quote

“The future belongs to those who believe in the beauty of their dreams.”

- Eleanor Roosevelt-

---